Evonik Industries AG (ETR:EVK)
Germany · Delayed Price · Currency is EUR | Market Cap | 7.61B -6.6% |
| Revenue (ttm) | 13.72B -9.4% |
| Net Income | 157.00M -47.5% |
| EPS | 0.34 -47.6% |
| Shares Out | 466.00M |
| PE Ratio | 48.42 |
| Forward PE | 9.71 |
| Dividend | 1.00 (6.12%) |
| Ex-Dividend Date | Jun 4, 2026 |
| Volume | 783,872 |
| Open | 16.33 |
| Previous Close | 16.39 |
| Day's Range | 16.32 - 16.49 |
| 52-Week Range | 12.49 - 18.32 |
| Beta | 0.53 |
| Analysts | Hold |
| Price Target | 17.65 (+7.16%) |
| Earnings Date | Aug 4, 2026 |
About Evonik Industries AG
Evonik Industries AG operates as a chemicals company in the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. It operates through the Advanced Technologies, Custom Solutions, and Infrastructure segments. The Advanced Technologies segment provides polymers for medical applications; crosslinkers; hydrogen peroxide, a sterilizing agent for cleaning silicon wafers and a bleaching agent for the paper and textile industries; fumed and precipitated silicas and silanes for the automotive, tire, electronics, and cosmetics industries; and ... [Read more]
Financial Performance
In 2025, Evonik Industries AG's revenue was 14.07 billion, a decrease of -7.18% compared to the previous year's 15.16 billion. Earnings were 265.00 million, an increase of 19.37%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for EVK stock is "Hold." The 12-month stock price target is €17.65, which is an increase of 7.16% from the latest price.
News
Evonik Industries AG: Evonik invests US$100 million to upgrade its U.S. drug substance contract manufacturing site
Meets the growing demand for U.S.-based contract development and manufacturing organizations (CDMOs)Further improves capabilities to handle increasing complexity of active pharmaceutical ingredien...
Evonik Raises Performance Outlook Amid Supply Chain Disruptions
Evonik Raises Performance Outlook Amid Supply Chain Disruptions
Evonik Raises Guidance on Higher Prices, Cost Reductions
Evonik said it raised its guidance for the year on higher prices, higher sales volumes and cost reductions.
Evonik Industries: Q2 2026 financials and adjusted outlook for 2026
Evonik lifts its 2026 outlook as strong Q2 earnings, robust volumes and pricing, and supply-chain tailwinds fuel confidence—despite rising uncertainty for H2.
EQS-Adhoc: Evonik Industries AG: Current financial and forecast data for the second quarter of 2026 and adjustment of the outlook for the financial year 2026
EQS-Ad-hoc: Evonik Industries AG / Key word(s): Forecast / Full year/Results / Half year Evonik Industries AG: Current financial and forecast data for the second quarter of 2026 and adjustment of the ...
Evonik To Sell Pharma Ingredient Assets In Hanau To ProChem For Undisclosed Terms; Stock Up
BRUSSELS (dpa-AFX) - German specialty chemicals maker Evonik Industries AG (EVK.DE) announced on Friday that it is selling selected pharmaceutical ingredient production assets at its Hanau site in...
Evonik price target raised to EUR 17 from EUR 16 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Evonik (EVKIF) to EUR 17 from EUR 16 and keeps a Buy rating on the shares. The firm sees the company reporting…
Evonik Industries (EVKIF) to Cut 3,200 Jobs Amid Restructuring Efforts
Evonik Industries (EVKIF) to Cut 3,200 Jobs Amid Restructuring Efforts
Evonik to cut 3,200 jobs worldwide by 2029, as it extends restructuring programme
Evonik Industries will cut 3,200 jobs worldwide by the end of 2029, including 2,150 positions in Germany, the German chemicals group said on Thursday.
EQS-AFR: Evonik Industries AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Evonik Industries AG / Preliminary announcement on the disclosure of financial statements Evonik Industries AG: Preliminary announcement of the publicat...
Evonik Industries AG Transcript: Investor update
Resilience, sustainability, and innovation are integrated to address global challenges and drive growth. Key initiatives include advanced biosolutions, green hydrogen, and circular economy solutions, supported by a restructured R&D organization and international hubs.
Evonik downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Evonik (EVKIF) to Neutral from Buy with a price target of EUR 19, down from EUR 20. The firm made seven rating changes in European chemicals, “positioning…
Evonik price target raised to EUR 20 from EUR 17 at Citi
Citi analyst Sebastian Satz raised the firm’s price target on Evonik (EVKIF) to EUR 20 from EUR 17 and keeps a Buy rating on the shares.
Evonik Industries AG Transcript: AGM 2026
The meeting addressed leadership changes, a challenging financial year, and a shift to a performance-based dividend policy. Strategic initiatives focus on innovation, cost discipline, and green transformation, with continued investment in growth areas.
Evonik downgraded to Underweight from Neutral at JPMorgan
JPMorgan downgraded Evonik (EVKIF) to Underweight from Neutral with a EUR 14 price target as part of a broader sector note on European Chemicals. Mid-term earnings and ROIC outlook remains…
Evonik downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Evonik (EVKIF) to Equal Weight from Overweight with a price target of EUR 18, up from EUR 17. The firm sees a fair valuation following the post-earnings rally.
Evonik upgraded to Buy from Hold at Jefferies
Jefferies analyst Marcus Dunford-Castro upgraded Evonik (EVKIF) to Buy from Hold with a price target of EUR 20, up from EUR 15.10. The firm citing elevated methionine spreads and the…
Evonik price target raised to EUR 16 from EUR 15 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Evonik (EVKIF) to EUR 16 from EUR 15 and keeps a Hold rating on the shares.
Evonik price target raised to EUR 19 from EUR 18 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Evonik (EVKIF) to EUR 19 from EUR 18 and keeps an Overweight rating on the shares.
Evonik Industries AG Earnings Call Transcript: Q1 2026
Q1 2026 adjusted EBITDA exceeded expectations at EUR 475 million, driven by strong Advanced Technologies and pre-buying effects, while free cash flow remained robust. Q2 EBITDA is guided to at least EUR 550 million, but risks from inflation and supply chain disruptions persist.
Evonik Industries AG Slides: Q1 2026
Evonik Industries AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
Evonik Industries AG Quarterly report: Q1 2026
Evonik Industries AG has published its Q1 2026 quarterly earnings report on May 8, 2026.
Evonik Industries AG Earnings release: Q1 2026
Evonik Industries AG released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Evonik Industries AG Slides: Company presentation
Evonik Industries AG has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Evonik price target raised to EUR 15 from EUR 13 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Evonik (EVKIF) to EUR 15 from EUR 13 and keeps a Hold rating on the shares.